TP53 and non-small cell lung carcinoma: Surprisingly, combining rigosertib with a murine double minute 2 (MDM2) inhibitor resulted in a synergistic activity that induced apoptosis in NSCLC cells, although the results were limited by acquired p53 mutations [81].